Systemic Pharmacokinetics of Everolimus Eluted From the Absorb Bioresorbable Vascular Scaffold
Authors:
- David G. RizikDRDavid G. Rizik
- Louis CannonLCLouis Cannon
- Gregg W. StoneGSGregg W. Stone
- Maureen KennedyMKMaureen Kennedy
- Karine Piard-RusterKPKarine Piard-Ruster
- Peter StaehrPSPeter Staehr
- Stephen G. EllisSEStephen G. Ellis
- Dean J. KereiakesDKDean J. Kereiakes
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Evaluation of a fully bioresorbable vascular scaffold in patients with coronary artery disease: Design of and rationale for the ABSORB III randomized trialAmerican Heart Journal, 2015
- Pharmacokinetic Sub‐Study in the SPIRIT III Randomized and Controlled Trial of XIENCE V® Everolimus Eluting Coronary Stent SystemJournal of Interventional Cardiology, 2010
- Systemic exposure of everolimus after stent implantation: A pharmacokinetic studyAmerican Heart Journal, 2008
- Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid TumorsJournal of Clinical Oncology, 2008
- Therapeutic Drug Monitoring for Everolimus in Heart Transplant Recipients Based on Exposure–Effect ModelingAmerican Journal of Transplantation, 2004